Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Mirtazapine recalled?

Not under an active recall. Mirtazapine was recalled 9 times in the past — all now closed. Most recent: Mar 18, 2020.

Most common reason: Labeling / mix-up (4 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Mirtazapine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Mirtazapine recalls on record

none so far in 2026; 9 on record, newest first
Class II · Moderate risk

Mirtazapine Tablets

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Terminated Packaging defect Aurobindo Pharma USA Inc. NDC 13107-031-34 D-1235-2020
Class I · High risk

Mirtazapine Tablets

Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.

Terminated Labeling / mix-up AuroMedics Pharma LLC NDC 13107-001-05 D-0637-2020
Class I · High risk

Mirtazapine Tablets

Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.

Terminated Labeling / mix-up AuroMedics Pharma LLC NDC 13107-031-05 D-0636-2020
Class II · Moderate risk

Mirtazapine Tablets

Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled

Terminated Particulate / foreign matter Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-088-20 D-0493-2017
Class II · Moderate risk

Mirtazapine active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-801-2015
Class II · Moderate risk

MIRTAZAPINE Tablet

Labeling:Label Mixup; MIRTAZAPINE Tablet, 7.5 mg may be potentially mislabeled as ISONIAZID, Tablet, 300 mg, NDC 00555007102, Pedigree: W003691, EXP: 6/26/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-646-2014
Class II · Moderate risk

MIRTAZAPINE Tablet

Labeling:Label Mixup; MIRTAZAPINE Tablet, 7.5 mg may be potentially mislabeled as BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg, NDC 00574010603, Pedigree: AD73525_40, EXP: 5/30/2014; DULoxetine HCl DR, Capsule, 20 mg, NDC 00002323560, Pedigree: W003005, EXP: 6/11/2014; carBAMazepine ER, Tablet, 100 mg, NDC 00078051005, Pedigree: W003330, EXP: 6/18/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-645-2014